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Toxicology of Octabromobiphenyl and
Decabromuodiphenyl Oxide
by J. M. Norris,* R. J. Kociba,* B. A. Schwetz,* J. 0. Rose,* C. G. Humiston,*
G. L. Jewett,* P. J. Gehring,* and J. B. Mailhest
Decabromodiphenyl oxide (DBDPO) and octabromobiphenyl (OBBP) perform well
as fire-retardant additives for thermoplastics. Both compounds have low acute oral
toxicity and low skin absorption toxicity. They are neither primary skin irritants or
skin sensitizers and are only mildly irritating to the eyes. A 30-day dietary feeding
study in rats established 8 mg DBDPO/kg-day as an unequivocal no-effect level and
80 mg/kg-day as a marginal effect level. A no-effect level was not established for OBBP
in a comparative study. A 2-yr rat study providing 0.1 mg DBDPO/kg-day in the diet
revealed the bromine concentration reached a plateau in the liver within 30 days, while
the concentration in adipose tissue slowly increased. A comparable OBBP study revealed
bromine concentration in the liver and adipose tissue increased steadily and rapidly
with no attainment of a plateau during 180 days of the study. Neither compopnd produced
an accumulation of bromine in other tissues. After administration of 14C DBDPO, all
4C activity was eliminated via the feces within 2 days. After administration of IC
OBBP, 62% was eliminated with a half-life of less than 24 hr; the half-life for the
remainder was greater than 16 days. In a teratology study, 10, 100, or 1000 mg DBDPO/
kg-day had no effect in rats. Reproductive capacity of rats was not effected at 3, 30, or
100 mg DBDPO/kg-day. No effects were observed on cytogenetic examination of bone
marrow cells of parents and weanlings from the reproduction study.
Introduction
Flame retardancy is required for high per-
formance thermoplastic resins because of their
use in electrical and high temperature applica-
tions. Two compounds which meet stringent
thermal stability requirements for these ap-
applications are decabromodiphenyl oxide
(DBDPO) and octabromobiphenyl (OBBP).
DBDPO has also found acceptance as a flame-
retardant (FR) agent for high-impact poly-
styrene, ABS, polyethylene, adhesives, thermo-
set polymer applications of epoxy resins, and
unsaturated polyesters and in textile coating
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formulations. Since the toxicological properties
of fire-retardant chemicals are a major factor
in determining suitability for large scale use,
the studies summarized in this paper were
undertaken. The studies were intended to evalu-
ate the toxicity of the materials and assess the
potential hazards associated with their manu-
facture and use and to determine if these mate-
rials, like the structurally similar polychlorin-
ated biphenyls, are absorbed and retained by
the body.
Materials
The structure and properties of commercially
produced decabromodiphenyl oxide (DBDPO)
and octabromobiphenyl (OBBP) are sum-
marized in Table 1.
The composition of the OBBP and DBDPO
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Table 1. Properties of commercial decabromodiphenyl oxide (DBDPO) and octabromobiphenyl (OBBP).
DBDPO OBBP
Structure
0 Br4
Br, Br6 Br4
Empirical formula C12Br10O C12Br8H2
Bromine, % 83 82
Molecular weight 960 786
Melting range, °C 290-306 200-250
Decomposition point (DTA), °C 425 435
Volatility, TGA (10°C/min) °C
< 1% wt. loss 300 250
<10% wt. loss 330 310
<50% wt. loss 370 350
Vapor pressure, mm Hg
At 2500C <1
At 278°C 2
At 3060C 5
Solubility at 25°C
Water, ppb 20-30 20-30
Cottonseed oil, ppm 600 1700
Solubility in organic solvents, g/100 g solvent
Acetone 0.05 1.80
Benzene 0.48 8.10
Chlorobenzene 0.60 18.70
Methylene bromide 0.42 7.40
Methylene chloride 0.49 3.90
o-Xylene 0.87 10.00
Octanol: water partition coefficient 172,000 340,000
samples used in the toxicological studies was
determined by vapor phase chromatography
and mass spectrophotometry. The OBBP sam-
ple contained 45.2% OBBP, 47.4% nonabromo-
biphenyl, 5.7% decabromobiphenyl, and 1.8%
heptabromobiphenyl. The composition of the
sample of DBDPO (Dow FR-300-BA, Specifi-
cation Number D37968) was 77.4%o DBDPO,
21.8% nonabromodiphenyl oxide, and 0.8%o
octabromodiphenyl oxide.
Experimental
Range-finding acute oral studies on OBBP
and DBDPO were conducted on female Sprague-
Dawley rats (Spartan strain); New Zealand
albino rabbits were used in routine eye and
skin irritation studies. A repeated insult patch
test was conducted on 50 human subjects to
assess the skin sensitization potential of
DBDPO. The rabbit ear bioassay test for
bromacnegenic activity was conducted on both
materials according to published procedures
(1,2). Thirty-day feeding studies utilized male
Sprague-Dawley rats which were maintained
on diets providing 800, 80, 8, or 0 mg of OBBP
or DBDPO/kg-day. A 2-yr dietary feeding study
in male and female rats providing dose levels
of 1.0, 0.1, 0.01, or 0 mg of DBDPO./kg-day is
on-going. A comparable study with OBBP was
terminated after 8 months because of the likeli-
hood that this material would bioaccumulate
in the environment. Parameters monitored in
the dietary feeding studies included the fol-
lowing: body weights, food consumption, ap-
pearance and demeanor, routine hematologic
determinations, urinalysis, serum enzyme activ-
ity, organ weights, and gross and histopatho-
logical examination of tissues. In addition, at
various times during a 2-yr period, tissues of
rats receiving the aforementioned dietary levels
of OBBP or DBDPO were analyzed for bromine
by neutron activation analysis. Studies on the
elimination of bromine from tissues were con-
ducted on rats maintained for 90 days on diets
containing 1.0 mg of OBBP or DBDPO/kg-day
and then placed on a diet of untreated feed for
designated periods up to 90 days for recovery.
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corn oil, was administered to male and female
Sprague-Dawley rats at a dose of 1 mg/kg, and
excretion of the radioactivity was measured at
24-hr intervals over a 16-day period. Radio-
activity in various tissues of the 14C-OBBP- or
14C-DBDPO-treated rats was determined on
days 1, 3, and 16. Pregnant female Sprague-
Dawley rats on a teratology study were admin-
istered 1000, 100, 10, or 0 mg of DBDPO/kg
on days 6-15 of gestation followed by cesarean
section on day 21 of gestation. The maternal
animals were evaluated for appearance and
demeanor, food consumption, body and liver
weights, and bromine concentration in liver
tissue. Teratological examinations for effects
on fetal body measurements, incidence of fetal
resorptions and anomalies were conducted.
Bromine concentration in fetal liver tissue was
determined. Male and female rats on a repro-
duction study were provided diets containing
100, 30, 3, or 0 mg DBDPO/kg-day for 60 days
before being mated. Parameters monitored in-
cluded the following: body weights, food con-
sumption, length of time between the first day
of cohabitation and parturition, number of
live and dead newborn, number of live pups at
days 1, 7, 14, and 21, litter weights at days
1, 7, and 14, individual weanling weights at
day 21, sex of each weanling at days 1 and 21,
abnormalities noted on day 21, organ weights,
and gross and pathological examination of
tissues from parental weanling animals and
cytogenetic examination of bone marrow cells
from parental and weanling animals.
Results
Acute Oral Toxicity of OBBP and DBDPO
Intragastric intubation of a single dose of
a 10%o corn oil suspension of OBBP or DBDPO
to female rats that had been deprived of food
for approximately 15 hr resulted in the survival
of all rats at dose levels of 126, 252, 500, 1000,
or 2000 mg/kg. There were no indications of
toxicity among the OBBP or DBDPO treated
rats directly after intubation or during the
14-day post-treatment observation period. All
animals displayed body weight gains over the
14-day observation period. Gross pathological
examination of one rat/dose level of OBBP
or DBDPO, 24 hr after treatment, revealed no
detectable pathological changes.
Skin Irritation of OBBP and DBDPO
Skin irritation studies conducted on shaved
skin of rabbits showed that OBBP and DBDPO,
as dry solids, caused essentially no response
on intact skin and a slight erythematous and
edematous response on abraded skin after a
single confined exposure of 24 hr. Repeating
the exposures to intact skin for 5 days/week
for 2 weeks and to abraded skin for 3 days
did not alter the responses. OBBP moistened
with water caused no response on intact skin
and a moderate erythematous and slight edem-
atous response on abraded skin after 24 hr of
confined contact. Repeating the exposures
caused a slight erythematous response on the
intact skin and no alteration in the response
of abraded skin. After cessation of treatment,
the erythematous and edematous responses
subsided and at the termination of the study
all skin sites were normal in appearanee. No
changes in appearance or demeanor, or effects
on body weights were observed.
Eye Irritation of OBBP and DBDPO
Eye irritation studies conducted on rabbits
showed that OBBP or DBDPO, as dry solids,
caused transient irritation of the conjunctival
membranes of washed and unwashed eyes. The
cornea, iris, and lens were unaffected. The eyes
of the rabbits showed no conjunctival mem-
brane irritation 24 hr after instillation of either
experimental material.
Human Skin Sensitization Study on DBDPO
Repeated application of a homogenous 5%o
suspenion of DBDPO in petrolatum, three times
per week for three weeks, to the skin of 50
human subjects resulted (3) in no skin sensiti-
zation response during the "sensitizing" period
or on challenge 2 weeks subsequent to the last
application.
Bromacnegenic Activity of OBBP and
DBDPO
Bioassay tests for possible bromacnegenic
activity conducted on the ear of rabbits showed
that OBBP or DBDPO, as 10%o chloroform solu-
tions, caused a slight erythematous response
and slight exfoliation during the month-long
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response on the ears treated with either experi-
mental material at any time during or at the
termination of the study.
30-Day Rat Dietary Feeding Studies on
OBBP and DBDPO
Male rats maintained on diets containing 1.0,
0.1, 0.01, or 0%o OBBP or DBDPO providing
approximate dose levels of 800, 80, 8, or 0
mg/kg-day showed no changes in appearance
or demeanor during the 30-day study. Inclusion
of OBBP or DBDPO at any level in the diets
did not influence the food consumption or body
weight gains of the respective experimental
animals. Hematology studies conducted during
the terminal week of the study showed statisti-
cally significant decreased packed cell volume
and total red blood cell count of rats on the
1% dietary level of OBBP. The hematological
determinations on the rats on the 0.1 and
0.01% dietary levels and on the rats receiving
diets containing 1.0%o DBDPO were not sta-
tistically different than the rats on the control
diet.
Urinalyses made during the terminal week
of the study showed no difference in total solids,
pH, sugar, albumin, occult blood, and ketones
of rats on diets containing OBBP or DBDPO
when compared with rats on the control diet.
A comparison of organ weights showed no
dose-related statistical difference in heart,
testes, or brain from rats on diets containing
OBBP or DBDPO or in the weight of kidneys
from rats on diets containing DBDPO.
Enlarged livers were found in the rats on all
dietary levels of OBBP and those rats on the
1.0 and 0.19 levels of DBDPO. Increased kid-
ney weights were found in rats on diets con-
taining 1.0 and 0.19 OBBP.
Gross pathological changes that were ob-
served at necropsy were limited to dose-related
liver enlargement in rats at all dose levels of
OBBP and those on the 1.0%o dietary level of
DBDPO. Kidney changes, consisting of peti-
chial hemorrhage, enlargement, and mottling,
were noted only in some of the rats on diets
containing OBBP.
The histopathological examination of organs
and tissues of the rats on the experimental
diets revealed liver and kidney lesions at all
levels of OBBP and at the 1.0%o dietary level
of DBDPO. The liver lesions consisted of cen-
trilobular cytoplasmic enlargement and vacuo-
lation; the kidney lesions consisted of hyaline
degenerative cytoplasmic changes. The other
dose related pathological finding was thyroid
hyperplasia which was observed in rats on all
levels of OBBP and those rats on the 1.0 and
0.1% dietary levels of DBDPO.
14C Metabolism Studies on OBBP and DBDPO
'4C-labeled OBBP and DBDPO used in these
studies had specific activities of 1.1 /uCi/mg.
The level of radioactivity found in the urine
and expired air of three male and three female
rats dosed with 1.0 mg of OBBP or DBDPO/kg
suspended in corn oil and measured at 24-hr in-
tervals over a 16-day period was less than 1%o.
The principal route of excretion for these ma-
terials was via the feces. The respective rates of
excretion of OBBP or DBDPO were the same
for both sexes. The mean values of 14C activity
found in the feces of the group of three male
rats/experimental material are graphed in
Figure 1. Within the first 24 hr, 90.6%o + 1.21
(mean and standard error) of the 14C activity
of the dose administered to the DBDPO-treated
rats was found in the feces, and 99+%o of the
14C activity was accounted for by day 2 of the
study.
In contrast, 61.9%o ± 2.39 of the 14C activity
administered to the OBBP-treated rats was
found in the feces after the first 24 hr. From
day 2 through day 16, there was a gradual
elimination of approximately llgo in addition,
7% of which was accounted for during the
second 24-hr period after treatment. At the
termination of the study, on day 16, 26.42%o
± 1.43 of the 14C activity in the administered
dose had not been recovered in the excreta.
Examination for radioactivity of various
tissues taken from three male rats per time
period following administration of the experi-
mental materials, revealed 14C activity in all
tissues taken from the OBBP-treated rats on
day 1 and at lower levels in tissues taken from
the DBDPO-treated rats.
On day 16, 14C activity was found in the
adrenals, adipose tissue, heart, and skin at
levels ranging from 0.14 to 0.25%'o of the
administered dose per gram of tissue from the
OBBP-treated rats. Lesser amounts were found
in liver, pancreas, and spleen (0.019 + 0.00,
0.06% + 0.07, and 0.03 + 0.04, respectively).
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and urinalyses on five rats/sex/dose level at
1 yr were unremarkable.
Rats maintained for 8 months on the OBBP
diets likewise showed no overt indications of
adverse effects due to treatment. There were
no dose-related deaths; the body weights and
food consumption of the rats on the experi-
mental diets were not different than the con-
trols. Organ weight measurements taken at
necropsy showed increased absolute and rela-
tive liver weights at the highest dose level. The
findings of the other parameters were not
different than the controls.
Tissue Accumulation Studies on Rats
Maintained on Diets Containing OBBP or
DBDPO
DBDPO
0 2 4 6 8 10
Time In Days
These studies designed to run concomitantly
with the 2-yr dietary feeding studies are on-
going. Male and female rats maintained on
diets providing 1.0, 0.1, 0.01, and 0 mg of
OBIBP and DBDPO/kg-day during the first
180 days of the study have shown that the
bromine concentration in kidney, skeletal
muscle, serum, and testes of the treated rats
was not different from that of controls.
Subsequent analyses of these tissues were,
12 14 16 therefore, not conducted. The mean bromine
content of liver and adipose tissue of rats on
receiving 0.1 mg/kg-day of OBBP or DBDPO
for 180 days is presented in Figures 2 and 3,
FIGURE 1. 14C Activity remaining in the body as a
function of time following the administration of
1.0 mg of labeled octabromobiphenyl or decabromobi-
phenyl oxide/kg of three male rats.
In contrast, the tissues taken from DBDPO-
treated rats on day 16 showed no 14C activity
with the exception of the adrenal (0.01 0.06
of the dose administered/gram of tissue) and
splenic tissue (0.06% + 0.07 of dose admin-
istered/gram of tissue). The 14C activity in
these tissues was at the limit of detection.
Two-Year Dietary Feeding Studies on OBBP
and DBDPO
Eighteen months into the 2-yr study on
DBDPO, the rats have shown no overt indica-
tions of adverse effects due to treatment. There
have been no dose-related deaths; the body
weights and food consumption of the rats on
the experimental diets are not different than
-9 15
I
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FIGURE 2. Bromine content of liver tissue from rats
maintained on diets providing a dose of 0.1 mg/kg-
day of octabromobiphenyl or decabromodiphenyl
oxide.
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FIGURE 3. Bromine content of adipose tissue from
rats maintained on diets providing a dose of 0.1
mg/kg-day of octabromobiphenyl or decabromodi-
phenyl oxide.
respectively. On the basis of regression analy-
sis there was obviously an increase in the
bromine concentration in these tissues of the
OBBP-treated rats. Statistical analysis by use
of the Student's t test showed that the bromine
concentration in the adipose and liver tissue
of the OBBP-treated rats was significantly in-
creased at the p<0.01 level on day 180 when
compared with the controls. The bromine con-
tent of the liver of DBDPO-treated rats was
not significantly different from the control,
whereas the bromine content of the adipose
tissue from these rats was statistically in-
creased at the p<0.05 level when the data
were analyzed for difference in slope by using
a log linear relationship. However, analyses
made after 12 months on the DBDPO diets
showed the bromine concentration in the adi-
pose tissue as well as in the liver was not
increased when compared with the controls.
Studies on the Elimination of Bromine from
Tissues of Rats Maintained on Diets
Containing OBBP or DBDPO
Male rats maintained for 90 days on diets
providing a dose of 1.0 mg of OBBP or
DBDPO/kg-day and then placed on control
diets of untreated feed were sacrificed on the
last day on the experimental diets, recovery
day 0, and on recovery days 10, 30, 60, and 90.
Kidney, serum, adipose tissue, and liver tissue
were analyzed for bromine by neutron activa-
tion analysis. On recovery day 0, there was no
DBDPO
'--I '''.---------- --------------- Control
I I I I I
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Days On Recovery
FIGURE 4. Bromine content of adipose tissue from
rats on recovery following 90 days on diets providing
1.0 mg/kg-day of octabromobiphenyl or decabromodi-
phenyl oxide.
difference in bromine content in kidney or
serum of rats on the OBBP or DBDPO diets
when compared with the respective tissues of
control rats. The bromine content in adipose
and liver tissue on the various recovery days
is given in Figures 4 and 5. Higher levels of
bromine were found in these tissues of the
OBBP-treated rats than in the respective
tissues of DBDPO-treated rats. The respective
bromine concentrations in the adipose tissue of
the OBBP- and DBDPO-treated rats remained
unchanged during the recovery period. There
was partial elimination of bromine from the
livers of the OBBP-treated rats during the first
30 days on recovery, whereas after 10 days on
recovery the bromine concentration in the liver
of the DBDPO rats did not differ from that of
control liver tissue.
Teratology Study on DBDPO
Daily intubation, by intragastric gavage, of
pregnant females on gestation days 6-15, with
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FIGURE 5. Bromine content of liver tissue from rats
on recovery following 90 days on diets providing
1.0 mg/kg-day of octabromobiphenyl or decabromodi-
phenyl oxide.
1000, 100, 10, or 0 mg of DBDPO/kg, suspended
in corn oil, caused no teratogenic response
at any dose level. There were no indications of
toxicity among the rats during gestation. The
maternal body weights and food consumption
of the DBDPO treated rats did not differ from
control rats.
The terminal liver weight of the DBDPO-
treated rats, obtained at the time of cesarean
section, were not different from those of the
controls. Similarly, no differences were seen
between the treated and control rats with re-
spect to the position and number of fetuses
in utero; the number of corpora lutea; indi-
vidual pup weight, crown rump ratio and male/
female sex ratio. Significant incidences in re-
sorptions occurred at the low dose levels but
not at the high dose level.
No gross external abnormalities were seen
in the fetuses from dams treated at any dose
level of DBDPO. Soft tissue (4) and skeletal
examinations (5) revealed an increased num-
ber of litters with subcutaneous edema and
delayed ossification of normally developed bones
of the skull of the fetuses of dams at the 1000
mg/kg level of DBDPO but not at the 100
mg/kg level.
Analysis of the maternal and fetal livers for
'bromine revealed statistically significant in-
creased concentration in the livers of the
maternal anmials receiving 1000 mg/kg-day of
DBDPO. The concentrations in maternal livers
at the two lower dose levels were not different
from those of the controls. Likewise, there
was no difference in the bromine concentration
in the livers of the fetuses from dams receiving
any dose level of DBDPO when compared with
the controls.
Reproduction Study on DBDPO
The reproductive capacity of rats was not
affected by diets providing 100, 30, or 3 mg/kg-
day of DBDPO given for 90 days prior to
mating as well as during mating, gestation
and lactation. The per cent and number of
pregnancies, pup survival indices, neonatal
body weights, male/female ratio on day 21,
and the length of time between the first day
of cohabitation and delivery were not affected
by the inclusion of DBDPO in the diets. Fur-
thermore, examination of the neonates at
weaning revealed no treatment-related effects.
Cytogenetic examination of bone marrow cells
taken at necropsy from the femur of the treated
parental animals as well as from the neonates
at weaning showed no increase in cytogenetic
aberrations when compared with controls.
Summary and Discussion of the Toxicological
Investigations
Octabromobiphenyl and decabromodiphenyl
oxide may be considered to present a low
degree of hazard from acute exposure. Both
experimental materials are low in acute oral
toxicity. They are neither eye nor skin irritants
nor skin sensitizers (3,6). OBBP and DBDPO
are not absorbed through the skin (6) in acutely
toxic amounts, and they do not possess bromac-
negenic activity.
Dietary feeding studies conducted over a wide
range of dose levels for 30 days to elucidate
the potential hazard that might be incurred
through long-term repeated exposure, resulted
in an unequivocal "no-effect" level of 0.01%o
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DBDPO, with a marginal effect level of 0.1%
(approximately 80 mg/kg-day). In contrast, a
no-effect level was not established for OBBP
in a 30-day period at these high dose levels.
Thyroid hyperplasia seen in rats at all dose
levels of OBBP and the top two dose levels of
DBDPO was quite possibly a physiological
response to competition between bromine and
iodine in the thyroid gland. Such a response
is not unexpected at high dose levels with
materials containing bromine in quantities as
great as in OBBP and DBDPO.
DBDPO did not cause a teratogenic response
in fetuses of rats administered 1000, 100, or
10 mg of DBDPO/kg-day on gestation days
6-15. No indications of toxicity, adverse effects
on food consumption, or body or liver weights
were observed in the maternal rats at any of
the dose levels of DBDPO. At the high dose
level, the bromine content of the maternal
livers was increased. The bromine content of
fetal livers, was, however, unaffected by the
administration of DBDPO to maternal rats at
any dose level included in this study.
The no-effect level in this teratology study
was 100 mg of DBDPO/kg-day. The number
of resorptions occurring at the two lower levels
of DBDPO was statistically greater than the
controls. However, as this effect did not occur
at the high dose level, it was probably due to
chance rather than treatment.
Fetal toxicity in the form of subcutaneous
edema was noted in fetuses of dams at the high
dose level of DBDPO. The only other effect
noted was delayed ossification of normally de-
veloped bones of the fetal skull occurring
similarly at the high dose level.
Aftosmis et al. (7) have reported that OBBP
administered in diets of pregnant rats caused
a teratogenic response, gastroschisis, in some
of the fetuses of dams on diets containing 0.1
and 1.0%o of OBBP. The bromine content was
increased in the liver and fat of the OBBP
treated maternal rats and also in the whole
fetus.
The reproductivity of rats chronically main-
tained on diets containing DBDPO was un-
affected at the highest dose level administered,
100 mg/kg-day. Inclusion of DBDPO in the
diet had no detrimental effect on the resultant
offspring and no cytogenetic effects were seen
in parental or weanling bone marrow cells.
The data from the 30-day dietary feeding
study and the teratology study indicate that
the degree of hazard that exists from long-term
exposure to DBDPO is significantly less than
to OBBP. The 14C metabolism study, reproduc-
tion study, and the special studies on absorption,
accumulation, and elimination, which were
subsequently conducted, offer additional sub-
stantiation for this observation.
The results of the metabolism study show
that the half-life for the disappearance of 14C
activity from the body of DBDPO-treated rats
was less than 24 hr. The disappearance of 14C
activity from the body of OBBP-treated rats
was biphasic. The half-life of the first phase
was less than 24 hr, the second phase greater
than 16 days. The principal route of excretion
for both experimental materials was via the
feces. No appreciable 14C activity (less than
1%) was found in either urine or expired air.
There were no sex-related differences in the
way these materials were excreted by the rats.
Examination of the various tissues for radio-
activity at 1, 3, and 16 days following admin-
istration of OBBP and DBDPO labeled with
14C revealed that absorption had occurred with
both materials. The levels of 14C activity in the
various tisues of the OBBP-treated rats were
greater than those found in the corresponding
tissues of DBDPO-treated rats. The 14C activity
readily cleared from the tissues of the DBDPO-
treated rats, whereas on day 16, the last day
of the study, 14C activity persisted in the
adrenal tissue, skin, adopose tissue, and heart
of the OBBP-treated rats.
The results of the metabolism study further
suggest that DBDPO does not have the poten-
tial of OBBP to bioaccumulate. The special
tissue accumulation study revealed that after
180 days, there was no accumulation of OBBP
or DBDPO in serum, kidney, skeletal muscle,
or testes of rats on diets providing 0.1 mg/kg-
day. The sites of deposition were the liver and
adipose tissue. The bromine content increased
rapidly in both these tissues of the OBBP-
treated rats. The bromine content of the livers
of the DBDPO-treated rats reached a plateau
after 30 days. The bromine concentration in
the livers of the DBDPO-treated rats sacrificed
after 180 days on tests were not statistically
different from those of the controls. Analysis
of the data on the bromine content in adipose
tissue of DBDPO treated rats over a 12-month
Environmental Health Perspectives 160period revealed no accumulation in this tissue.
The special study on the elimination of bro-
mine from various tissues of rats maintained
for 90 days on diets providing 1.0 mg of OBBP
or DBDPO/kg-day revealed high levels of
bromine in the liver and adipose tissue of the
OBBP-treated rats and low levels in the
DBDPO-treated rats. Bromine was not elimi-
nated from adipose tissue of the OBBP-treated
rats and only partially eliminated from the liver
of these rats after 90 days on recovery.
The low level of bromine in adipose tissue
of the DBDPO-treated rats remained unaffected
during the 90 days on recovery diets. The bro-
mine concenration in the liver of these rats
was not significantly higher than in the control
livers after the first 10 days' recovery.
The in-depth toxicological investigation on
DBDPO is continuing to be pursued by The
Dow Chemical Company.
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